


## Biomimetic Syntheses of Heptaketide Metabolites: Alternariol and a Derivative of Rubrofusarin

By FINIAN J. LEEPER and JAMES STAUNTON\*

(University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW)

**Summary** Biogenetically inspired syntheses of alternariol and a methyl ether of rubrofusarin are described.


THE fungal metabolite alternariol<sup>1</sup> (1) is presumed to arise by cyclisation of a heptaketide folded as in Scheme 1. In principle the process could take place in two stages and



SCHEME 1

hence follow alternative pathways (a) or (b). A biomimetic synthesis of alternariol based on pathway (a) has been described;<sup>2</sup> we now describe one modelled on pathway (b). The synthesis could be varied to produce the naphthopyrone (9), a methyl ether of rubrofusarin (10).

Treatment of methyl dimethyl orsellinate with lithium di-isopropylamide in tetrahydrofuran (THF) at  $-78^{\circ}\text{C}$  generates the anion<sup>†</sup> (4) (Scheme 2) which reacts with the pyrylium salt (5)<sup>3</sup> to give, after aqueous work-up, the pyrone (6)<sup>‡§</sup> (m.p.  $125^{\circ}\text{C}$ ;  $\nu$  1720 and  $1665\text{ cm}^{-1}$ ) in 25–35% yield, among other products. This was treated with sodium hydroxide in aqueous methanol; acidic work-up gave alternariol dimethyl ether<sup>‡</sup> (7) in 83% yield with identical spectral properties to those reported,<sup>4</sup> m.p.  $292^{\circ}\text{C}$  (decomp.) (lit. m.p.  $292\text{--}294^{\circ}\text{C}$ ). The product was demethylated<sup>4</sup> to alternariol<sup>‡</sup> (1),  $350^{\circ}\text{C}$  (decomp.) [lit.



SCHEME 2. i, OH<sup>-</sup>; ii, conc. HI; iii, LiNPri<sub>2</sub>.

m.p.  $349\text{--}350^{\circ}\text{C}$  (decomp.)). This synthesis can be commended not only for its relevance to a possible biosynthetic route but also for being more efficient than existing routes to alternariol.<sup>1,2,4</sup>

The formation of (7) is presumably initiated by hydrolytic cleavage of the pyrone ring of (6) to give a triketone (8). The almost complete regioselectivity in the cyclisation of this intermediate is unusual for an *in vitro* reaction. Interestingly, none of the naphthalene (9) could be detected by t.l.c. in the crude reaction mixture. However, this product could be formed at the expense of the biphenyl by treatment of the pyrone (6) with strong non-nucleophilic base (*e.g.*, lithium di-isopropylamide); a mixture of products was obtained from which the naphthalene<sup>†</sup> was isolated [17% (27% based on unrecovered starting material)] with identical spectral properties to those reported,<sup>5</sup> m.p.  $210\text{--}214^{\circ}\text{C}$  (lit. m.p.  $213^{\circ}\text{C}$ ).

This work shows that pathway (b) (Scheme 1) for the biosynthesis of alternariol is no less attractive on chemical grounds than pathway (a).<sup>6</sup> On biosynthetic grounds, the former seems more likely since unlike the latter it conforms

<sup>†</sup> We are indebted to G. E. Evans of this laboratory for this finding.

<sup>‡</sup> For this compound, n.m.r., i.r., u.v., and mass spectra as well as microanalysis or high resolution mass measurement were in agreement with the assigned structure.

<sup>§</sup> This pyrone formed a hydrochloride which crystallized from ether and melted with loss of HCl at *ca.*  $70^{\circ}\text{C}$  then resolidified and melted again at the m.p. of the pyrone.

to an almost universal feature of polyketone cyclisations *in vivo*: thus it involves an intermediate benzene derivative in which the attached residue bearing the chain starter unit is longer than that bearing the chain building unit.<sup>7</sup> In view of the highly regiospecific cyclisation of (8) *in vitro*, it is

possible that *in vivo* this reaction might take place independently of an enzyme.

We thank the S.R.C. for financial support.

(Received, 20th February 1978; Com. 182.)

<sup>1</sup> H. Raistrick, C. E. Stickings, and R. Thomas; *Biochem. J.*, 1953, **55**, 421.

<sup>2</sup> T. M. Harris and J. V. Hay; *J. Amer. Chem. Soc.*, 1977, **99**, 1631.

<sup>3</sup> D. A. Griffin and J. Staunton, *J.C.S. Chem. Comm.*, 1975, 675.

<sup>4</sup> F. Soti, M. Incze, M. Kajtar-Peredy, E. Baitz Gacs, L. Imre, and L. Farkas; *Chem. Ber.*, 1977, **110**, 979.

<sup>5</sup> S. Shibata, E. Morishita, and Y. Arima; *Chem. and Pharm. Bull. (Japan)*, 1967, **15**, 1757.

<sup>6</sup> For discussion of chemical factors, see ref. 2.

<sup>7</sup> W. B. Turner, 'Fungal Metabolites,' Academic Press, London and New York, 1972, p. 198.